SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

SAN

103.98

+0.48%↑

SHL.DE

55.4

+0.54%↑

PHIA

24.26

+0.96%↑

SRT3

241.7

-2.89%↓

ORNBV.FI

52.44

-0.19%↓

Search

Merck KGaA

Cerrado

135.5 -0.7

Resumen

Variación precio

24h

Actual

Mínimo

135.1

Máximo

135.65

Métricas clave

By Trading Economics

Ingresos

202M

809M

Ventas

-194M

5.3B

P/B

Media del Sector

26.27

73.394

BPA

2.2

Rentabilidad por dividendo

1.34

Margen de beneficio

15.363

EBITDA

85M

1.6B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+30.26 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.34%

3.09%

Próximas Ganancias

6 mar 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

33B

98B

Apertura anterior

136.2

Cierre anterior

135.5

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Merck KGaA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2025, 07:03 UTC

Adquisiciones, fusiones, absorciones

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

14 nov 2024, 08:09 UTC

Ganancias

Merck KGaA Earnings Growth Beats Expectations -- Update

14 nov 2024, 06:26 UTC

Ganancias

Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss

11 feb 2025, 16:45 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk

11 feb 2025, 10:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

6 ene 2025, 13:08 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA: Transaction closed on Dec. 23, 2024

6 ene 2025, 13:07 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA: Didn't Disclose Financial Details

6 ene 2025, 13:06 UTC

Adquisiciones, fusiones, absorciones

Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio

6 ene 2025, 13:04 UTC

Adquisiciones, fusiones, absorciones

Merck KaA Acquires HUB Organoids Holding B.V. to Expand Its Next-Generation Biology Portfolio

17 dic 2024, 13:05 UTC

Adquisiciones, fusiones, absorciones

Merck: Deal Expected to Close By End Dec. 2024

17 dic 2024, 13:04 UTC

Adquisiciones, fusiones, absorciones

Merck: Terms of Deal Undisclosed

17 dic 2024, 13:04 UTC

Adquisiciones, fusiones, absorciones

Merck Signs Pact to Buy HUB Organoids

17 dic 2024, 13:03 UTC

Adquisiciones, fusiones, absorciones

Merck: Acquisition Advances Next Gen Biology Portfolio

17 dic 2024, 13:03 UTC

Adquisiciones, fusiones, absorciones

Merck to Buy HUB Organoids Holding

14 nov 2024, 11:15 UTC

Charlas de Mercado

Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk

14 nov 2024, 10:45 UTC

Charlas de Mercado
Ganancias

Merck KGaA's Life-Science Sales Recovery Is Encouraging -- Market Talk

14 nov 2024, 09:26 UTC

Charlas de Mercado
Ganancias

Merck KGaA's Electronics Division Disappointed -- Market Talk

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Sees 2024 EBITDA Before One-Time Items Around Mid-Point Of Range

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Had Seen 2024 Net Sales Between EUR20.7B and EUR22.1B

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA 3Q EBITDA EUR1.55B .

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Sees 2024 EPS Pre Around Mid-Point of EUR8.20 to EUR9.30

14 nov 2024, 06:00 UTC

Ganancias

Analysts Saw Merck KGaA 3Q Ebitda Before One-Time Items at EUR1.55B

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Backs 2024 View

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA 3Q Sales EUR5.27B

14 nov 2024, 06:00 UTC

Ganancias

Analysts Saw Merck KGaA 3Q Net Sales at EUR5.33B

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA: 3Q Life Science Returns to Organic Sales Growth

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Had Seen 2024 EBITDA Before One-Time Items Between EUR5.8B to EUR6.4B

14 nov 2024, 06:00 UTC

Ganancias

Merck KGaA Expects 2024 Net Sales In Lower Half Of Range

Comparación entre iguales

Cambio de precio

Merck KGaA Esperado

Precio Objetivo

By TipRanks

30.26% repunte

Estimación a 12 meses

Media 176.5 EUR  30.26%

Máximo 190 EUR

Mínimo 160 EUR

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck KGaA Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

6

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

134.7 / 135.55Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck KGaA

There is no Profile data available for MRK.BE.